Our CEO, Adam Bruce, will be attending BIO Europe Spring, March 18-20, Barcelona, Spain.
Reach out to schedule a meeting and learn more about our groundbreaking drug candidate ILB®, targeted at improving outcomes for people suffering from otherwise untreatable progressive and disabling neurodegenerative diseases, including:
✅ amyotrophic lateral sclerosis (ALS)
✅ stroke
✅ traumatic brain injury
✅ glaucoma